Report Description

Cancer is recognized as a major cause of mortality world over; accounting for 7.4 million (or 13%) of all deaths in 2004. The WHO estimates the incidence of cancer to continue rising to reach an estimated 9.2 million deaths in 2015. The rising prevalence of the disease forms one of the major factors driving the growth of the oncology biomarkers market.

Biomarker are chemical, physical, or biological parameters that can be used to indicate disease states. Oncology biomarkers facilitate high-speed, non-invasive cancer diagnosis; and are believed to enhance early cancer detection and screening. The demand for oncology biomarkers is also increasing because of their ability to trace the exact type of cancer and to target patient-specific molecular structure.

The oncology biomarkers market offers high-growth opportunities with the numerous initiatives to encourage biomarker-based cancer treatment. Government agencies such as Food and Drug Administration (FDA) and the National Cancer Institute (NCI) ) are have taken an active interest in the field, especially with the declining success to failure rate of oncology drugs

Market Estimates and Forecasts

The report categorizes the Global oncology biomarkers market as follows:

• Oncology biomarkers discovery market
• Oncology biomarkers diagnostics market

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 15 company profiles for each of its sub-segments.

What makes our reports unique?

• We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
• We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
• We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
• Comprehensive market analysis for the following sectors:

Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

• Which are the high-growth segments/cash cows and how is the market segmented in terms of oral drugs, injectables?
• What are market estimates and forecasts; which markets are doing well and which are not?
• Where are the gaps and opportunities; what is driving the market?
• Which are the key playing fields? Which are the winning edge imperatives?
• How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

TABLE OF CONTENTS

EXECUTIVE SUMMARY
MARKET OVERVIEW
MARKET DYNAMICS
CANCER BIOMARKERS DIAGNOSTICS MARKET
CANCER BIOMARKERS DISCOVERY MARKET
GEOGRAPHICAL ANALYSIS
COMPETITIVE LANDSCAPE

1 INTRODUCTION
  1.1 Key take-aways
  1.2 Report description
  1.3 Markets covered
  1.4 Research methodology
  1.5 Stakeholders
 
2 SUMMARY

3 MARKET OVERVIEW
  3.1 Introduction
  3.2 Defining the market
  3.3 Classification of cancer biomarkers
  3.4 Factors influencing market growth
  3.5 Market share analysis
  3.5.1 By market segments
  3.5.2 By market players
  3.6 Patent analysis
 
4 MARKET DYNAMICS
  4.1 Introduction
  4.2 Drivers
      4.2.1 Enhanced accuracy & speed of diagnosis
      4.2.2 Streamlined drug delivery process
      4.2.3 Increased survival rates
      4.2.4 Non-invasive diagnosis
      4.2.5 U.S. Government initiatives
      4.2.6 Helps in fda approvals for cancer drugs
      4.2.7 Demographic & other factors
  4.3 Restraints
      4.3.1 High cost & complexity of biomarker validation
      4.3.2 Reimbursement issues
      4.3.3 Other validation issues
      4.3.4 Need for immediate processing
 
5 CANCER BIOMARKERS DIAGNOSTICS MARKET
  5.1 Introduction
  5.2 Immunoassays
  5.3 Immunohistochemical (IHC) tests
  5.4 Molecular (DNA and genomic) diagnostic assays
  5.5 Genetic and genomic markers
  5.6 Proteomics
  5.7 Flow cytometry
  5.8 Stem cell markers
  5.9 Monoclonal antibodies
  5.10 Pharmacogenomics
  5.11 DNA microarrays
  5.12 IVD multivariate index assays (IVDMIA)
 
6 CANCER BIOMARKERS DISCOVERY MARKET
  6.1 Metabolomics
  6.2 Genetic methods
      6.2.1 DNA arrays
      6.2.2 Southern blot
      6.2.3 Polymerase chain reaction (PCR)
      6.2.4 Reverse transcriptase polymerase chain reaction (RT-PCR)
      6.2.5 Fluorescent in situ hybridization (FISH)
  6.3 Protein methods
      6.3.1 Immunohistochemistry (IHC)
      6.3.2 Mass spectrometry (MS)
  6.4 Imaging
      6.4.1 Positron emission tomography (PET)
      6.4.2 Computed tomography (CT)
      6.4.3 Magnetic resonance imaging (MRI)
      6.4.4 Magnetic resonance spectroscopy (MRS)
      6.4.5 Single-photon emission computed tomography (SPECT)
      6.4.6 X-ray
      6.4.7 Biophotonics
      6.4.8 Ultrasound
 
7 GEOGRAPHICAL ANALYSIS
  7.1 North America
  7.2 Europe
  7.3 Asia
  7.4 ROW
 
8 COMPETITIVE LANDSCAPE
 
9 COMPANY PROFILES
  9.1 ABBOTT LABORATORIES
  9.2 AFFYMETRIX, INC
  9.3 AGENDIA BV
  9.4 AMBRILIA BIOPHARMA
  9.5 ASTELLAS PHARMA US INC
  9.6 AUREON LABORATORIES, INC
  9.7 BECKMAN COULTER, INC
  9.8 BECTON, DICKINSON AND COMPANY
  9.9 BIOCUREX INC
  9.10 BIOMERIEUX S.A.
  9.11 BIOMODA, INC
  9.12 CLARIENT, INC
  9.13 CORRELOGIC SYSTEMS, INC
  9.14 DIADEXUS, INC
  9.15 DIAGNOCURE INC
  9.16 EPIGENOMICS AG
  9.17 EUSA PHARMA (USA) INC
  9.18 EXACT SCIENCES CORP
  9.19 FUJIREBIO DIAGNOSTICS, INC
  9.20 GEN-PROBE, INC
  9.21 GENOMIC HEALTH INC
  9.22 GERON CORP
  9.23 HOLOGIC INC
  9.24 IMMUNOMEDICS, INC
  9.25 INVERNESS MEDICAL INNOVATIONS, INC
  9.26 LABORATORY CORP. OF AMERICA HOLDINGS
  9.27 MORPHOTEK, INC
  9.28 MYRIAD GENETICS, INC
  9.29 NORTHWEST BIOTHERAPEUTICS INC
  9.30 OCIMUM BIOSOLUTIONS LTD
  9.31 ONCOTHYREON, INC
  9.32 POLYMEDCO INC
  9.33 PONIARD PHARMACEUTICALS INC
  9.34 QIAGEN N.V.
  9.35 RADIENT PHARMACEUTICALS CORP
  9.36 SIEMENS HEALTHCARE
  9.37 VERIDEX LLC
 
APPENDIX
U.S. Patents
Europe Patents
Japan Patents
 
LIST OF TABLES
 
Summary Table Global Cancer Biomarker Market, By Segments 2007-2014 ($Million)
 
1 List of FDA approved biomarkers
2 FDA initiatives for cancer biomarkers
3 Global cancer biomarker diagnostic market, by technologies 2007-2014 ($Million)
4 Global cancer biomarker diagnostic market, by geography 2007-2014 ($Million)
5 Global immunoassays market, by geography 2007-2014 ($Million)
6 Global immunohistochemical tests market, by geography 2007-2014 ($Million)
7 Global molecular (DNA and genomic) diagnostic assays market, By Geography  2007-2014 ($Million)
8 Global genomics and genetic markers market, by geography 2007-2014 ($Million)
9 Global proteomics market, by geography 2007-2014 ($Million)
10 Global flow cytometry market, by geography 2007-2014 ($Million)
11 Global stem cell markers market, by geography 2007-2014 ($Million)
12 Global monoclonal antibodies market, by geography 2007-2014 ($Million)
13 Global pharmacogenomics market, by geography 2007-2014 ($Million)
14 Global DNA microarrays market, by geography 2007-2014 ($Million)
15 Global in vitro diagnostic multivariate index assays market, by geography 2007-2014 ($Million)
16 Global cancer biomarker discovery market, by segments 2007-2014 ($Million)
17 Global cancer biomarker discovery market, by geography 2007-2014 ($Million)
18 Global metabolomics market, by geography 2007-2014 ($Million)
19 Global genetic methods market, by methods 2007-2014 ($Million)
20 Global genetic methods market, by geography 2007-2014 ($Million)
21 Global DNA arrays market, by geography 2007-2014 ($Million)
22 Global southern blot market, by geography 2007-2014 ($Million)
23 Global polymerase chain reaction market, by geography 2007-2014 ($Million)
24 Global reverse transcriptase polymerase chain reaction market, by geography 2007-2014 ($Million)
25 Global fluorescent in situ hybridization market, by geography 2007-2014 ($Million)
26 Global protein methods market, by segments 2007-2014 ($Million)
27 Global protein methods market, by geography 2007-2014 ($Million)
28 Global immunohistochemistry market, by geography 2007-2014 ($Million)
29 Global Mass spectrometry market, by geography 2007-2014 ($Million)
30 Global imaging market, by segments 2007-2014 ($Million)
31 Global imaging market, by geography 2007-2014 ($Million)
32 Global positron emission tomography market, by geography 2007-2014 ($Million)
33 Global computed tomography market, by geography 2007-2014 ($Million)
34 Global magnetic resonance imaging market, by geography 2007-2014 ($Million)
35 Global magnetic resonance spectroscopy market, by geography 2007-2014 ($Million)
36 Global single photon emission computed tomography market, by geography 2007-2014 ($Million)
37 Global x-ray market, by geography 2007-2014 ($Million)
38 Global biophotonics market, by geography 2007-2014 ($Million)
39 Global ultrasound market, by geography 2007-2014 ($Million)
40 Global cancer biomarkers market, by geography 2007-2014 ($Million)
41 North American cancer biomarkers market, by segments 2007 – 2014 ($Million)
42 European cancer biomarkers market, by segments 2007-2014 ($Million)
43 Asian cancer biomarkers market, by segments 2007-2014 ($Million)
44 Row cancer biomarkers market, by segments 2007-2014 ($Million)
45 Mergers and acquisitions (2008 - January 2010)
46 New product launches (2008 - March 2010)
47 Agreements and collaborations (2008 - January 2010)
  
LIST OF FIGURES
 
1 Cancer biomarker market segmentation
2 Classification of cancer biomarkers
3 Comparative analysis of market drivers
4 Comparative analysis of market restraints
5 Cancer biomarker diagnostics market dynamics
6 Market shares of major players in cancer biomarkers molecular diagnostics
7 Patent analysis by geography (2005 - 2009)
8 Patent analysis by competitors (2004 - March 2010)
9 Drug development process flow
9 Developments in global cancer biomarkers market (2008 – March 2010)
10 Key players in strategic development

Global Oncology Biomarkers Market

Biomarkers are chemical, physical, or biological parameters that can be used to indicate disease states. The global oncology biomarkers market is currently witnessing a high growth rate due to increase in number of cancer cases, especially gender specific cancers with increase in age. The market is expected to grow from $4.1 billion in 2009 to $9.5 billion in 2014 at a CAGR of 18.1% from 2009 to 2014.

Oncology biomarkers facilitate high-speed, non-invasive cancer diagnosis; and are believed to enhance early cancer detection and screening. The demand for oncology biomarkers is also increasing because of their ability to trace the exact type of cancer and to target patient-specific molecular structure.

The oncology biomarkers market offers high-growth opportunities with numerous initiatives to encourage biomarker-based cancer treatment. Government agencies such as Food and Drug Administration (FDA) and the National Cancer Institute (NCI) have taken an active interest in the field, especially with the declining success to failure rate of oncology drugs.

The overall market is segmented into the submarkets for biomarker-based cancer discovery and diagnostics. While the discovery market currently holds the larger market share, the diagnostic market is expected to have a higher CAGR.

North America holds the largest share of the global market for cancer biomarkers, generating revenues of $1.19 billion in 2009. An increasing demand for personalized treatment, strong government support, and a high rate of technology development and adoption form the major factors driving the growth of the North American market for cancer biomarkers.

The major players in the global oncology biomarkers report include Roche, Gen-probe, Affimetrix, and Abbott. The most common growth strategies adopted by these market players include agreements and collaborations to stabilize management costs and to take advantage of the core competencies of the partner company.